Viking Therapeutics, Inc. (VKTX)
- Previous Close
63.42 - Open
63.84 - Bid 63.77 x 300
- Ask 63.94 x 800
- Day's Range
62.30 - 64.94 - 52 Week Range
8.28 - 99.41 - Volume
1,559,887 - Avg. Volume
6,469,075 - Market Cap (intraday)
7.037B - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.91 - Earnings Date Apr 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
113.80
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
www.vikingtherapeutics.comRecent News: VKTX
Performance Overview: VKTX
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VKTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VKTX
Valuation Measures
Market Cap
7.04B
Enterprise Value
6.68B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
20.21
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-66.47
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.47%
Return on Equity (ttm)
-34.79%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-85.89M
Diluted EPS (ttm)
-0.91
Balance Sheet and Cash Flow
Total Cash (mrq)
362.08M
Total Debt/Equity (mrq)
0.36%
Levered Free Cash Flow (ttm)
-42.36M